Anika Therapeutics, Inc. Overview
Pro stress-test →Anika Therapeutics is a medical manufacturing company that develops, manufactures, and commercializes therapeutic products based on proprietary hyaluronic acid technology, specializing in orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions. The company focuses on joint preservation and restoration through early intervention products designed to help patients restore active living.
Strategic Profile
Pro stress-test →In October 2024, the company announced a strategic shift to focus on its profitable hyaluronic acid-driven OA pain management and high growth regenerative solutions portfolio, with the divestiture of Arthrosurface and planned sale of Parcus Medical, which it executed in March 2025. Commercial Channel revenue was up 22% with continued strong Integrity Implant System and Hyalofast growth, and double-digit International OA Pain Management growth.
Competitive Landscape
Pro stress-test →Anika's top competitors include Lifecore Biomedical, MannKind, Avita Medical America, and Arrowhead Pharmaceuticals. Anika competes in the orthopedic and joint preservation market with differentiated hyaluronic acid technology platform and regenerative solutions. The company is positioned as a leader in early intervention orthopedic care addressing osteoarthritis pain management and soft tissue repair.
Industry Context
Anika Therapeutics, Inc. operates in Medical Devices / Orthopedics / Joint Preservation.
Key facts
Founded: 1983 · Headquarters: Bedford, Massachusetts, US · Employees: 288 · Revenue: $119.9M